Advertising
Novavax injections are reserved for other people who have not yet been vaccinated, which is probably to restrict their consumption at first.
Send a story to any friend.
As a subscriber, you have 10 gift pieces to offer per month. Anyone can read what you share.
This article is from our coronavirus updates.
By Rebecca Robbins and Carl Zimmer
The Centers for Disease Control and Prevention on Tuesday will have a newly licensed Novavax vaccine used as an option for adults seeking the number one coronavirus vaccine.
Dr. Rochelle Walensky, director of the CDC, endorsed the advice of a vaccine expert organization that unanimously approved the vaccine Tuesday afternoon. The resolution is the main regulatory hurdle to making the fourth COVID-19 vaccine legal in the United States.
The Novavax vaccine is expected to play a limited role in the country’s vaccination campaign, at least initially. The Food and Drug Administration legalized it last week as the number one vaccine for adults, but it doesn’t yet have it as a booster.
Novavax, a Maryland-based pharmaceutical company, won significant federal investment to expand its vaccine, but fell far into the vaccine race. Still, he hopes the vaccine will appeal to Americans who have so far refused to get vaccinated.
Somewhere between 26 and 37 million adults in the United States have yet to get a coronavirus vaccine, according to survey data presented at the assembly by Dr. Julia S. SKatherine Fleming-Dutra of the CDC.
But in countries where it has been available for months, the Novavax vaccine has yet to have a significant effect on vaccination rates. Novavax said Tuesday in its presentation to the panel that just over a million doses of its vaccine had been administered internationally through the end of June, a minuscule figure compared to the success of competing injections.
Biden’s management said last week it would buy 3. 2 million doses of the two-shot Novavax vaccine, enough to fully vaccinate 1. 6 million more people in the United States. The vaccine is not yet available in pharmacies and other clinics that administer injections. Novavax said in a post-vote news release that the FDA had signed the first doses destined for the United States and that the company planned to ship its vaccine to a distribution center “in the coming days. “
With two doses spaced 3 weeks apart, the vaccine has been shown to offer a high degree of protection against severe coronavirus infections and illnesses in clinical trials. But these were done before the advent of the Omicron variant, which greatly reduced the efficacy of other legal vaccines in preventing infections.
The Novavax vaccine works from the three Covid vaccines in the past legal in the United States. It causes an immune reaction with nanoparticles composed of proteins from the surface of the coronavirus that causes Covid-19. Similar protein-based vaccines have been used around the world. for decades.
Dr. Evelyn Twentyman of the C. D. C. presented the effects of a survey that suggested that few unvaccinated Americans would decide on Novavax. Only 16% of unvaccinated respondents said they would “probably” or “definitely” get a protein-based covid vaccine, and 50% of unvaccinated respondents said they would “do. “probably” or “definitely” not.
At Tuesday’s meeting, CDC officials reviewed data from clinical trials that connected the vaccine to a high but low risk of the emerging bureaucracy of central inflammation known as myocarditis and pericarditis.
Dr. Filip Dubovsky, Novavax’s chief medical officer, told the assembly that the company monitors cases of central inflammation in countries where the vaccine is already licensed. Looking at just over a million doses, the company detected 17 safe or probable cases of myocarditis and pericarditis, he said.
Advertising